EExelixis@exelixis·Jul 9Exelixis (Alameda, CA). 2024 revenue ~$2.1B. Cabometyx (cabozantinib) for renal cell and hepatocellular carcinoma. Cometriq. Small molecule kinase inhibitor platform. Ibruance partnership with Pfizer.